GIQuIC Automation of Pathology Results

Now from Miraca

Avoid hours of manual data entry! Miraca pathology results now can populate the pathology section of the GIQuIC form automatically if you use gGastro® from gMed, a Modernizing Medicine company, or ProVation® MD from Wolters Kluwer. How is this automation possible? Miraca delivers highly structured pathology results through enhanced interfaces with gMed and ProVation MD,.

gGastro Capabilities

Pathology results for colonoscopies will populate automatically in the GIQuIC form.

ProVation MD Capabilities

Pathology results for single colonoscopies will populate automatically in the GIQuIC form. Additionally, the ProVation MD Adenoma Detection Rate report for physicians can be created automatically.

If your practice participates in the GIQuIC registry, you can avoid hours of manual data entry. Contact Miraca to get started: Call 1.866.588.3280 or email MiracaTechnology@MiracaLS.com.

What is GIQuIC?

The GI Quality Improvement Consortium, Ltd.—GIQuIC—is a non-profit collaboration of the American College of Gastroenterology (ACG) and the American Society for Gastrointestinal Endoscopy (ASGE), providing a quality benchmarking registry. Physicians are participating by collecting and submitting data about their colonoscopies. Participation in GIQuIC enables practices and centers to participate in PQRS reporting in order to avoid penalties by the Centers for Medicaid and Medicare Services (CMS).

Miraca Life Sciences provides fee-based consulting services to help clients understand their options for quality reporting and how to embed quality reporting into their practice or center. Quality reporting such as via GIQuIC is required for participation in the CMS programs Value-Based Modifiers and Merit-Based Incentive Payment System (MIPS) as the industry goes to a pay-for-performance model.

Contact Miraca Life Sciences to learn how Miraca can assist your practice
Call 1.866.588.3280 or email MiracaTechnology@MiracaLS.com

[Miraca’s] team has removed the chaos and confusion from MU/PQRS preparedness, and has brought us to a state of compliance in a few short months. To quote one of our staff, ‘Honestly I can’t say enough for what they have done for us.’
— Martha J. Maso, MD, MPH,
Dermatologist, Westwood Dermatology Group, Westwood, N.J.


READ MORE
Learn about Miraca's unmatched quality. We provide our clients with access to the highest quality AP services.

Recent News


May 22, 2017

Miraca Life Sciences Again Expands Therapeutic Drug Monitoring with Addition of First Biosimilar Inflectra®

IRVING, Texas, May 23, 2017 — Miraca Life Sciences, the largest U.S. independent anatomic pathology laboratory, has further expanded its InformTx™ therapeutic drug monitoring (TDM) capabilities with the addition of testing for Inflectra® (infliximab-dyyb), which is the first biosimilar drug in the test offering. Since launching InformTx in June 2016, Miraca Life Sciences has expanded the service from four to […]

Continue reading


April 18, 2017

Miraca Research News: Philips receives FDA clearance to market Philips IntelliSite Pathology Solution for primary diagnostic use in the US

Pathologists at Miraca Life Sciences contributed significantly in the development of a new product from Philips, the IntelliSite Pathology Solution. As one of four clinical study sites, Miraca Life Sciences participated in “one of the largest studies ever conducted to directly compare the use of digital pathology to optical microscopes.” At Miraca, participation in the Philips study was a project of Miraca […]

Continue reading


April 11, 2017

Ten Research Projects from Miraca Life Sciences Accepted for DDW Conference

IRVING, Texas, April 12, 2017 — Ten research projects from the GI pathologists at Miraca Life Sciences, the nation’s largest independent anatomic pathology lab, have been accepted for presentation at the Digestive Disease Week® conference (DDW), which will be held May 6–9 in Chicago. DDW is the world’s largest gathering of physicians, researchers and industry in the fields of gastroenterology, […]

Continue reading


March 27, 2017

Simponi® is Sixth Drug in InformTx™ Therapeutic Drug Monitoring Service from Miraca Life Sciences

IRVING, Texas, March 28, 2017 — Miraca Life Sciences, the largest U.S. independent anatomic pathology laboratory, continues to expand its InformTx™ therapeutic drug monitoring (TDM) capabilities, now testing for Simponi (golimumab) as well as patient-developed antibodies to Simponi. This is the first TDM assay available in the United States for Simponi. With this addition, Miraca Life Sciences now performs TDM […]

Continue reading


November 30, 2016

Stelara® Now Available for Therapeutic Drug Monitoring from Miraca Life Sciences

IRVING, Texas, December 1, 2016 — Miraca Life Sciences, the largest U.S. independent anatomic pathology lab, has expanded its InformTx™ therapeutic drug monitoring service for drugs that treat inflammatory bowel disease (IBD) with the addition of Stelara (ustekinumab).

Miraca Life Sciences continues to perform therapeutic drug monitoring (TDM) for Remicade® (infliximab), Humira® (adalimumab), Cimzia® (Certolizumab pegol) and Entyvio® (vedolizumab). Since […]

Continue reading